Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site
Chiesi Group and inhalation CDMO Bespak have expanded their long‑standing partnership by increasing pressurized metered‑dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel, UK site. The move supports Chiesi’s Carbon Minimal Inhaler (CMI) program, which targets up to a 90 % reduction in the carbon footprint of pMDIs through low‑global‑warming‑potential propellants. Both companies cite sustainability as a core strategic priority, aligning with Chiesi’s Net‑Zero by 2035 ambition and Bespak’s decarbonisation roadmap. The expanded collaboration positions the UK facility as a hub for next‑generation, low‑carbon inhaler production within the global supply chain.
Kurin Prevails in Federal Appellate Court in Long-Running Litigation with Magnolia Medical Technologies
Kurin, Inc. secured a victory in the United States Court of Appeals for the Federal Circuit, which affirmed a district‑court ruling that its Lock technology does not infringe Magnolia Medical Technologies' patents. The appellate decision removes legal uncertainty and validates...
Aplantex and Investissement Québec Team up to Produce Molecules for the Cosmetic and Food Industries
Aplantex has partnered with Investissement Québec to use its state‑of‑the‑art demonstration plant for green biotechnology extraction. The collaboration gives Aplantex access to advanced equipment and technical experts, enabling faster refinement of plant‑based molecules with antioxidant, anti‑inflammatory, antimicrobial and anti‑aging properties....
Gene Therapy for Duchenne Muscular Dystrophy: Genethon Confirms Two-Year Efficacy in Patients Treated with Its Drug Candidate GNT0004 at Therapeutic...
Genethon presented two‑year data from its dose‑escalation phase showing that GNT0004, administered at 3 × 10¹³ vg/kg, produced sustained functional gains and biomarker improvements in ambulatory DMD boys. Motor scores rose 9 points on the NSAA, the 6‑minute walk distance improved by...
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples
Eurofins Biomnis has developed and validated a new LC‑MS/MS method to detect and quantify cereulide toxin in human stool samples. The assay meets ISO 15189 requirements, accounting for matrix effects, and delivers turnaround times suitable for routine clinical labs. Cereulide, linked...
Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
DexCom will unveil new real‑world evidence at ATTD 2026 showing its CGM improves HbA1c in non‑insulin‑treated Type 2 patients, reduces DKA‑related hospitalizations in Type 1 patients, and supports a safe Smart Basal insulin‑optimization system. The company also detailed a product roadmap featuring...
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema...
Curatis Holding and Japan’s Neupharma have signed an exclusive licensing deal granting Neupharma rights to develop and market corticorelin (C‑PTBE‑01) for peritumoral brain edema (PTBE) in Japan. The agreement includes up to CHF 83.5 million in upfront and milestone payments and royalties...
Bausch + Lomb Launches R&D “Teach-In” Webinar Series
Bausch + Lomb announced the kickoff of an R&D “Teach‑in” webinar series, beginning with a March 23 session focused on its glaucoma pipeline. Executive Vice President of R&D Yehia Hashad and senior leaders will discuss ELios™, an implant‑free laser glaucoma surgery already launched in...
HeartBeam to Attend Investor and Industry Conferences in March, Focused on Providing Updates on Commercial Launch and Unveiling 12-Lead ECG...
HeartBeam Inc. announced that its executive team will attend three major investor and industry conferences in March 2026, including Oppenheimer’s virtual MedTech summit, the ROTH conference, and the American College of Cardiology’s ACC.26. The CEO and CFO will present a...
AN2 Therapeutics Announces $40 Million Private Placement Financing
AN2 Therapeutics announced a $40 million private placement, selling 8,245,611 common shares at $2.85 each and offering pre‑funded warrants for up to 5,789,493 additional shares. The placement, backed by Coastlands Capital, Commodore Capital, Vivo Capital and other investors, is slated to...
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
Pulse Biosciences reported long‑term results from its first‑in‑human nPulse Vybrance study, showing an average 74% reduction in benign thyroid nodule volume after 15‑22 months. The data, presented at the 2026 North American Society for Interventional Thyroidology meeting, revealed no nodule...
Bristol Myers Squibb Announces Positive Phase 3 Results From the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple...
Bristol Myers Squibb reported positive interim Phase 3 results from the SUCCESSOR‑2 study, showing that oral mezigdomide combined with carfilzomib and dexamethasone (MeziKd) significantly extended progression‑free survival versus carfilzomib‑dexamethasone alone in relapsed or refractory multiple myeloma. The trial marks the first...
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
Daiichi Sankyo and AstraZeneca have received FDA priority review for ENHERTU® as a post‑neoadjuvant therapy in HER2‑positive early breast cancer. The decision follows the DESTINY‑Breast05 phase 3 trial, which showed a 53% reduction in invasive disease‑free survival events versus trastuzumab‑emtansine (T‑DM1). Three‑year...
Telestroke Services Market Projected to Reach $7.2 Billion by 2033 as Stroke Rates Rise and Rural Access Gaps Widen
Stroke incidence in the United States is climbing, with an 8% rise overall and a 15% surge among adults under 65, while neurologist wait times exceed three months. These trends create urgent demand for telestroke platforms that connect remote specialists...
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology
Mosaic Clinical Technologies announced that its AI unit Cognita received FDA Breakthrough Device Designation for Cognita Chest X‑Ray (CXR), the first generative vision‑language model in radiology to earn this status. The designation grants prioritized FDA interaction, potentially accelerating clearance. Internal...
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.
GAIA and Daiichi Sankyo Europe announced an exclusive partnership to commercialize lipodia, a digital therapeutic for hypercholesterolemia, pending regulatory approval. The agreement gives Daiichi Sankyo exclusive rights in Germany with plans to expand across Europe, leveraging GAIA’s evidence‑based platform and Daiichi’s cardiovascular...
Tandem Mobi Now Compatible with Android Smartphones
Tandem Diabetes Care announced that its Tandem Mobi insulin pump is now compatible with Android smartphones in the United States via a newly released mobile app. The Android version received FDA clearance in November 2025 and entered a limited rollout in...
Harrison.ai Continues to Grow Open Platform Ecosystem, Welcomes Four New AI Partners
Harrison.ai announced that four AI companies—AIRAmed, Koios Medical, Lunit and Nanox AI—are joining its Open Platform, expanding the catalog of imaging solutions across X‑ray, CT, MRI, mammography and ultrasound. The platform maintains a vendor‑neutral, zero‑mark‑up model, allowing healthcare organizations to...
RecovryAI Announces FDA Breakthrough Device Designation for Patient-Facing Clinical AI
RecovryAI, emerging from stealth, received FDA Breakthrough Device Designation for its physician‑prescribed Virtual Care Assistants (VCAs), AI tools that guide patients through post‑operative recovery. The designation, reserved for devices that can substantially improve care standards, accelerates the company’s engagement with...
Resilience Care & InterSystems Partner to Streamline Oncology Care Pathways
InterSystems and Resilience Care have formed a technology partnership to integrate Resilience Care’s remote‑monitoring platform with InterSystems IRIS for Health, streamlining oncology care pathways. The integration layer connects hospital information systems, automates data exchange for chemotherapy, lab, and imaging appointments,...
Medimaps Group and Radiobotics Announce Strategic Merger to Expand AI-Driven Musculoskeletal Imaging Portfolio
Medimaps Group and Radiobotics have agreed to merge, forming a global AI‑driven musculoskeletal imaging company. The combined entity will deliver an end‑to‑end suite across X‑ray and DXA, including automated fracture detection, opportunistic bone fragility assessment, and fracture‑risk prediction. It will...
Otsuka Medical Devices/Otsuka Pharmaceutical: Paradise Ultrasound Renal Denervation System for the Treatment of Resistant Hypertension, Now Covered by Insurance and...
Otsuka Medical Devices and Otsuka Pharmaceutical announced that Japan’s National Health Insurance will cover the Paradise™ Ultrasound Renal Denervation (uRDN) system starting March 1, with commercial sales beginning March 2. The device, developed by Recor Medical, targets resistant‑hypertension patients who remain uncontrolled...
RevolutionEHR Launches RevPay, Redefining How Optometry Practices Manage Cash Flow
RevolutionEHR introduced RevPay, an embedded payments solution that integrates checkout, patient records, and reporting within its AI‑native platform. The tool supports card, ACH, digital wallets and offers optional patient surcharging, promising to reduce processing fees that can cost $10,000‑$18,000 annually...
Median Technologies to Present at the TD Cowen 46th Annual Health Care Conference
Median Technologies announced it will present at TD Cowen’s 46th Annual Health Care Conference in Boston from March 2‑4, 2026. CEO Fredrik Brag will discuss the company’s latest AI‑driven SaMD developments and upcoming milestones on March 4 at 11:10 am ET. The presentation will be...
CFG Health Launches CareLink™ — A Fully Integrated, 24/7 Telehealth Platform for Correctional Health Care
CFG Health launched CareLink, a proprietary 24/7 telehealth platform designed for correctional facilities. Built on existing security‑issued tablets, the solution delivers emergency triage, primary, behavioral, and specialty care while maintaining HIPAA compliance. The platform combines CFG’s in‑house clinicians with external...
Acupath Laboratories, Inc. Partners with Azer Scientific to Install the First AzerView Digital Pathology Scanner in the United States
Acupath Laboratories has partnered with Azer Scientific to install the first AzerView LH510 digital pathology scanner in the United States. The LH510 offers high‑resolution whole‑slide imaging and streamlined workflow features designed for clinical, academic, and reference labs. The installation marks...
Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data
Cowellnex Co., Ltd. and Metagen, Inc. will begin joint research in February 2026 to create new gut‑microbiota test items and a personalized food‑recommendation algorithm using Cowellnex’s three‑year shotgun metagenomic dataset. The partnership leverages Cowellnex’s high‑precision Japanese microbiome data and Metagen’s...
Weave to Present at Raymond James 47th Annual Institutional Investors Conference
Weave (NYSE: WEAV), the AI‑driven patient engagement SaaS provider, announced it will present at the Raymond James 47th Annual Institutional Investors Conference on March 2, 2026 in Orlando. CEO Brett White and CFO Jason Christiansen will lead a fireside‑chat at 4:35 pm ET, followed by...
Sun Nuclear QADS 2026 Event Combines Clinical Insight and New Innovations for Advancing Radiation Therapy QA
Sun Nuclear launched its 15th QA & Dosimetry Symposium (QADS) in Rome, gathering more than 230 clinical physicists from nearly 40 countries. The event introduced the Daily QA 4 Pro, a combined dosimetry‑imaging device designed to streamline daily machine quality checks. Demonstrations also...
Beyond Vitals Spot Checks: Sibel Health and LookDeep Health Combine Wearable Monitoring with Real-Time Bedside AI
Sibel Health and LookDeep Health announced a strategic partnership that merges Sibel’s FDA‑cleared ANNE® One wearable, which continuously captures clinical‑grade vitals, with LookDeep’s aimee™ bedside AI that adds real‑time visual and audio context. The combined platform targets emergency departments, general...
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy
Mevion Medical Systems announced that its S250‑FIT proton therapy system has received CE marking under EU MDR, allowing marketing and clinical use across the European Union. The compact, LINAC‑vault‑ready platform, already cleared by the U.S. FDA, fits into standard radiation...
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position...
Galderma announced that regulatory agencies in the European Union, United States and Canada have approved a new state‑of‑the‑art Restylane® syringe for use with its NASHA® lidocaine filler line. The device is cleared for a broad set of facial areas—including cheeks,...
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
HekaBio K.K. and Alpha Tau Medical have secured Japanese regulatory approval for Alpha DaRT, a diffusing alpha‑radiation therapy for unresectable locally advanced or recurrent head‑and‑neck cancer. The approval makes Japan the first country outside Israel to clear the device, positioning HekaBio...
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
Natera reported Phase 2 SINERGY trial results showing a 63% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma when treatment was adapted using Signatera circulating tumor DNA monitoring. Seventy‑four percent of the 27 patients were de‑escalated...
Epredia and Mindpeak Announce EU Distribution Agreement for AI-Powered Image Recognition in Cancer Diagnostics
Epredia and Mindpeak have signed a distribution agreement to bring Mindpeak’s AI‑driven image‑recognition software to Epredia’s European digital pathology customers. The AI modules deliver pixel‑level analysis for breast, lung, gastrointestinal cancers and biomarker quantification, operating without cloud connectivity to preserve...
Ambience Healthcare Recognized as 2026 KLAS/CHIME Trailblazer Award Winner
Ambience Healthcare was named the 2026 KLAS/CHIME Trailblazer Award winner, recognizing its leadership in AI‑driven clinical documentation and revenue integrity. The award, now in its second year, evaluates vendors on KLAS performance scores, client feedback, and measurable industry impact. Ambience’s...
Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology’s Most Critical Questions
Flatiron Health showcased its global Prostate and Bladder Cancer Panoramic datasets at the ASCO GU 2026 symposium, leveraging over 420,000 longitudinal patient records from the US, UK and Germany. Six research presentations highlighted critical gaps in genetic testing, equitable access...
Exact Sciences Stockholders Approve Acquisition by Abbott
Exact Sciences stockholders voted overwhelmingly—over 99% of votes representing roughly 67% of outstanding shares—to approve Abbott’s proposed acquisition of the cancer‑diagnostics firm. The deal values Exact Sciences at $105 in cash per share, subject to customary closing conditions. Abbott expects...
Science Corp. And Neurosoft Bioelectronics Announce Novel BCI Ecosystem Partnership
Science Corporation and Neurosoft Bioelectronics have signed a multiyear, multimillion‑dollar partnership granting Neurosoft access to Science’s full‑stack clinical‑grade BCI tools, known as the Science BCI Ecosystem. The deal lets Neurosoft develop minimally invasive, fully implantable brain‑computer interfaces for tinnitus, epilepsy...
WestFax Launches AI-Powered Intelligent Document Processing Platform for Healthcare
WestFax launched Comprehend, an AI‑powered Intelligent Document Processing platform for healthcare, now available across all its service tiers. The solution uses OCR, AI and FHIR‑aligned models to convert inbound fax, email and file‑based documents into searchable PDFs, classify types, and...
ALIS Releases New Clinical Benchmarking Report Analyzing Data From 28,800 Senior Living Residents
ALIS released its Q4 2025 ALIS 500 Clinical Report, the first senior‑living clinical benchmarking study covering 500 communities and 28,800 residents. The report delivers detailed data on resident age, prevalent chronic conditions, comorbidity patterns, and fall incidents, and is paired with an...
FNIH Biomarkers Consortium Study Shows “Clock Model” Blood Test Can Predict Onset of Alzheimer’s Symptoms Years in Advance
The FNIH Biomarkers Consortium unveiled a “clock model” that uses a single blood test to forecast Alzheimer’s disease symptom onset 3‑4 years before clinical presentation. The model aggregates plasma biomarkers into a temporal trajectory, and a new web‑based visualization tool...
SEQSTER Launches 1-Click Data Refinery™ to Power Scalable AI Across Clinical Trials
SEQSTER PDM, Inc. unveiled its 1-Click Data Refinery™ – an enterprise‑grade engine that converts raw, patient‑consented EHR data into clean, structured, AI‑ready records. The platform normalizes, deduplicates and harmonizes data across health systems, delivering longitudinal patient views suitable for rapid...
GekkoVet and Royal Canin Enter Latin America with Mexico Launch, Opening a New Continent in Their Global Partnership
GekkoVet and Royal Canin have launched their AI‑driven veterinary decision‑support platform in Mexico, marking the first rollout of the partnership in Latin America after a successful Asian pilot. The integration equips clinics with real‑time diagnostics, treatment recommendations, and drug information within...
Hana Health by DSS Imagetech Partners with Overture Life to Bring World-First Automated Egg-Freezing Technology to India
Hana Health by DSS Imagetech has signed an exclusive agreement with Overture Life to launch DaVitri, the world’s first automated egg‑freezing platform, in India. The system standardises the vitrification step of IVF, cutting variability and enabling clinics to handle more...